Integrating circulating miRNA analysis in the clinical management of lung cancer: Present or future?

Rita Lampignano, Vera Kloten, Thomas Krahn, Thomas Schlange
2020 Molecular Aspects of Medicine  
Liquid biopsy holds great promise to complement traditional analysis on cancerous tissue during clinical management of cancer: screening of patients, (early) disease diagnosis, prognosis, therapy selection as well as early response to treatment and disease monitoring. Among emerging circulating biomarkers, cell-free miRNA (cfmiRNA) may have potential in detecting lung cancer and following the course of the disease. Furthermore, several studies highlighted the possibility to utilize these
more » ... tilize these regulatory RNAs to obtain prognostic information as well as to verify patient's response towards treatment. However, despite these findings, cfmiRNA is not used in the clinical practice as biomarkers to date, since their clinical utility and validity has not been confirmed in prospective clinical studies yet. In addition, there is no consensus on standardized (pre)analytical procedures. In this review, we present an overview of cfmiRNA biomarker candidates for clinical management of lung cancer and we discuss the issue of assay standardization.
doi:10.1016/j.mam.2020.100844 pmid:31959359 fatcat:kezyqjp4obeepilrgjwe5itqxe